Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Haemophilus b Conjugate Vaccine Clear all
Completed Phase 2 Interventional Results available

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00459290
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
mifepristone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 1, 2026, 2:24 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

NCT01732198
View directory record Official record
Conditions
Infectious Disease
Interventions
NU300, ActHIB, Prevnar 13
Biological
Lead sponsor
Nuron Biotech Inc.
Industry
Eligibility
12 Months to 15 Months
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Oakland, California • Bardstown, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders

NCT01178385
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, Treatment as Usual
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

NCT04450693
View directory record Official record
Conditions
Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions
TTAX01, Standard care
Biological · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
16
States / cities
Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 1, 2026, 2:24 PM EDT
Active, not recruiting Not applicable Interventional Results available

DCD IIT: Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors

NCT05462041
View directory record Official record
Conditions
Organ Transplant
Interventions
DBD Donor Heart Transplantation, DCD Donor Heart Transplantation
Other · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

NCT04978818
View directory record Official record
Conditions
Haemophilus Influenzae Type B Infection
Interventions
Vaxelis, PedvaxHIB
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
6 Weeks to 12 Weeks
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Anchorage, Alaska • Chinle, Arizona • Fort Defiance, Arizona + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

NCT03620162
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13™, V114, RotaTeq™, Pentacel™, RECOMBIVAX HB™, HIBERIX™, M-M-R™ II, VARIVAX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

NCT00112489
View directory record Official record
Conditions
Sarcoma
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
99
States / cities
Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

NCT01545375
View directory record Official record
Conditions
Infections, Streptococcal
Interventions
Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,806 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

NCT00687687
View directory record Official record
Conditions
Uterine Carcinosarcoma
Interventions
paclitaxel, carboplatin, BSI-201 (Iniparib)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
40
States / cities
Aurora, Colorado • Englewood, Colorado • New Britain, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 1, 2026, 2:24 PM EDT
Withdrawn Phase 3 Interventional

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

NCT01605084
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

NCT04557735
View directory record Official record
Conditions
Thrombotic Microangiopathy
Interventions
Ravulizumab, Best Supportive Care
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

NCT01049035
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 365 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)

NCT05145387
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
9 Years to 13 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT03734016
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Zanubrutinib, Ibrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Little Rock, Arkansas • Los Angeles, California • Boulder, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT02106546
View directory record Official record
Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Roo Study on Mom and Baby Well-Being

NCT03809598
View directory record Official record
Conditions
Maternal Psychological Distress, Prenatal Stress, Infant Development, Functional Neuroimaging, Pregnancy Related
Interventions
Mindfulness Based Cognitive Therapy
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Days to 45 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism

NCT01563003
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions
Cognitive Behavioral Therapy, Treatment as usual
Other
Lead sponsor
University of South Florida
Other
Eligibility
11 Years to 16 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 1, 2026, 2:24 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of California's Armed and Prohibited Persons System

NCT02318732
View directory record Official record
Conditions
Violence
Interventions
APPS intervention
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 2:24 PM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

NCT00311311
View directory record Official record
Conditions
Atherosclerosis, Kidney Failure
Interventions
tacrolimus, mycophenolate mofetil, prednisone, sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

NCT01659996
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions
Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 18 Months
Enrollment
1,394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Not applicable Interventional

Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy

NCT02391324
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Lokomat (LOK), Gait focused physical therapy (fPT), LOK + fPT
Procedure
Lead sponsor
University of Alberta
Other
Eligibility
5 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 1, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer

NCT04411810
View directory record Official record
Conditions
Skin Cancer
Interventions
Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 1, 2026, 2:24 PM EDT